Immunotherapy directed against private tumor neo-antigens derived from non-synonymous
somatic mutations is a promising strategy of personalized cancer immunotherapy. However …

Mutated cancer antigens, or neoantigens, represent compelling immunological targets and
appear to underlie the success of several forms of immunotherapy. While there are …

Background Efficient identification of neoantigen-specific T-cell responses in epithelial
ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell …

Purpose: This was a study prospectively evaluating intratumoral T-cell responses to
autologous somatic mutated neoepitopes expressed by human metastatic ovarian cancers …

Despite repeated associations between T cell infiltration and outcome, human ovarian
cancer remains poorly responsive to immunotherapy. We report that the hallmarks of tumor …

The cellular adaptive immune system mounts a response to many solid tumours mediated
by tumour‐infiltrating T lymphocytes (TILs). Basic measurements of these TILs, including …

Immunotherapies can mediate regression of human tumors with high mutation rates, but
responses are rarely observed in patients with common epithelial cancers. This raises the …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …

Mutation-derived neoantigens are important targets for T cell-mediated reactivity toward
tumors and, due to their unique tumor expression, an attractive target for immunotherapy …

Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) targeting neoantigens
can mediate tumor regression in selected patients with metastatic epithelial cancer …